^
Association details:
Biomarker:MTAP deletion
Cancer:Solid Tumor
Drug:MRTX1719 (PRMT5 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2779 / 2 - Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers

Published date:
03/15/2023
Excerpt:
MRTX1719 inhibited the growth of an extensive panel of MTAP del cell line-derived and patient-derived xenograft tumor models across various indications.